TABLE 3.
Effect of genotyping on dosage, indicated as percentage of commonly prescribed dosage, as indicated by KNMP (01-01-2019) or Stingl et al. (2013).
| Medicine | CYP2D6 | CYP2C19 | Relevant enzymes# | ||||
|---|---|---|---|---|---|---|---|
| PM | IM | UM | PM | IM | UM | ||
| Amitriptyline | 50% | 60% | 125% | 70* | 80%* | 140%* | CYP2D6, CYP2C19 |
| Aripiprazol | max 10 mg/dag | 100% | 100% | 70%* | 90%* | 140%* | CYP2D6, CYP3A4 |
| Citalopram | 100% | 100% | 100% | 50% | 75% | 100% | CYP2D6, CYP2C19, CYP3A4 |
| Clomipramine | 50% | 70% | 150% | 65%* | 75%* | 130%* | CYP2D6, CYP2C19 (CYP3A4, CYP1A2) |
| Doxepine | 40% | 80% | 200% | 50% | 90% | 120% | CYP2D6 (CYP1A2, CYP3A4, 2C19) |
| Escitalopram | 100% | 100% | 100% | 50% | 75% | 150% | CYP2C19 (CYP3A4, CYP2D6) |
| Fluoxetine | 100% | 100% | 100% | CYP2D6 (CYP2C19) | |||
| Haloperidol | 50% | 100% | NB | CYP2D6, CYP3A4 | |||
| Imipramine | 30% | 70% | 170% | 70% | 100% | 100% | CYP2D6, CYP2C19 |
| Nortriptyline | 40% | 60% | 160% | CYP2D6, CYP2C19 | |||
| Mirtazapine | 100% | 100% | 100% | CYP2D6, CYP1A2, CYP3A4 | |||
| Paroxetine | 100% | 100% | NB | CYP2D6 | |||
| Pimozide | 25% | 60% | 100% | CYP2D6, CYP3A4, CYP1A2 | |||
| Risperidon | 100% | 100% | 100% | CYP2D6 (CYP3A4) | |||
| Sertraline | 100% | 100% | 100% | max 50 mg/dag | Max 100 mg | 100% | CYP2C19 (CYP2D6, CYP2C9, CYP2B6, CYP3A4) |
| Venlafaxine | Not yet evaluated | Not yet evaluated | 150% | 40%* | 90%* | 125%* | CYP2D6, CYP3A4 |
| Zuclopentixol | 50% | 75% | Not yet evaluated | ||||
Of note: these percentages do not take into account co-medication, age, diet, renal function or comorbidity. Enzymes between brackets only have a minor contribution in the metabolization. Also, see www.kennisbank.knmp.nl for recent updates or consult a pharmacologist or PharmD. *.